GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poxel SA (XPAR:POXEL) » Definitions » COGS-to-Revenue

Poxel (XPAR:POXEL) COGS-to-Revenue : 1.00 (As of Dec. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Poxel COGS-to-Revenue?

Poxel's Cost of Goods Sold for the six months ended in Dec. 2022 was €0.59 Mil. Its Revenue for the six months ended in Dec. 2022 was €0.59 Mil.

Poxel's COGS to Revenue for the six months ended in Dec. 2022 was 1.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Poxel's Gross Margin % for the six months ended in Dec. 2022 was 0.34%.


Poxel COGS-to-Revenue Historical Data

The historical data trend for Poxel's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poxel COGS-to-Revenue Chart

Poxel Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.00

Poxel Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.47 1.00 1.00

Poxel COGS-to-Revenue Calculation

Poxel's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.672 / 0.674
=1.00

Poxel's COGS to Revenue for the quarter that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.589 / 0.591
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poxel  (XPAR:POXEL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Poxel's Gross Margin % for the six months ended in Dec. 2022 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.589 / 0.591
=0.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Poxel COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Poxel's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Poxel (XPAR:POXEL) Business Description

Traded in Other Exchanges
N/A
Address
259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

Poxel (XPAR:POXEL) Headlines

No Headlines